Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis

Anti-Cancer Drugs

Volumn 18, Issue 3, 2007, Pages 349-355

  Cuneo, Kyle C ^a   Fu, Allie ^a   Osusky, Katherine L ^a   Geng, Ling ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Metastasis; Prostacyclin; SU5416; Vascular endothelial growth factor receptor inhibition

Indexed keywords

1,1' DIOCTADECYL 3,3,3',3' TETRAMETHYLINDOCARBOCYANINE; PROSTACYCLIN; SEMAXANIB; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOMA CELL; CELL ADHESION; CHEMICAL LABELING; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEWIS CARCINOMA; LIVER; LUNG METASTASIS; LUNG PARENCHYMA; LUNG WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SYSTEMIC THERAPY; THROMBOCYTE ACTIVATION;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL ADHESION; CELLS, CULTURED; DISEASE PROGRESSION; EPOPROSTENOL; INDOLES; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SPLENIC NEOPLASMS;

EID: 33846688590     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328011fdab     Document Type: Article

References (39)

1. Roos E, Dingemans KP. Mechanisms of metastasis. Biochim Biophys Acta 1979; 560:135-166.
2. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79:185-188.
3. Tang DG, Honn KV. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis 1994; 14:109-122.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
5. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
6. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award lecture. Cancer Res 1986; 46:467-473.
7. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-18.
8. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175:409-416.
9. D'Amore PA. Antiangiogenesis as a strategy for antimetastasis. Semin Thromb Hemost 1988; 14:73-78.
10. Jendraschak E, Sage EH. Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. Semin Cancer Biol 1996; 7:139-146.
11. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59:99-106.
12. Lu H, Lin C, Zheng Z, Li S, Guo S, Zhang X, et al. Angiogenesis inhibitor Z24 induces endothelial cell apoptosis and suppresses tumor growth and metastasis. J Pharmacol Sci 2005; 97:533-540.
13. Bergsland EK. Vascular endothelial growth factor as a therapeutic target in cancer. Am J Health-Syst Pharm 2004; 61:S4-S11.
14. Gasic GJ, Gasic TB, Murphy S. Anti-metastatic effect of aspirin. Lancet 1972; 2:932-933.
15. Honn KV, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent. Science 1981; 212:1270-1272.
16. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999; 91:22-36.
17. Honn KV. Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin Exp Metastasis 1983; 2:103-114.
18. Crissman JD, Hatfield JS, Menter DG, Sloane B, Honn KV. Morphological study of the interaction of intravascular tumor cells with endothelial cells and subendothelial matrix. Cancer Res 1998; 48:4065-4072.
19. Gasic GJ. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev 1984; 3:99-114.
20. Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 1992; 11:325-351.
21. Lin WC, Pretlow TP, Pretlow TG, Culp LA. Bacterial lacZ gene as a highly sensitive marker to detect micrometastasis formation during tumor progression. Cancer Res 1990; 50:2808-2817.
22. Adams JY, Johnson M, Sato M, Berger F, Gambhir SS, Carey M, et al. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 2002; 8:891-897.
23. Paris S, Sesboue R. Metastasis models: the green fluorescent revolution? Carcinogenesis 2004; 25:2285-2292.
24. Chishima T, Miyagi Y, Wang X, Yamaoka H, Shimada H, Moossa A, et al. Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res 1997; 57:2042-2047.
25. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic hu7 man cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 2001; 19:940-945.
26. Izycki D, Gryska K, Grabarczyk P, Wysocki PJ, Jarosinska A, Nawrocki S, et al. Flow cytometric cytotoxicity assay with GFP gene modified target cells. Adv Exp Med Biol 2001; 495:429-434.
27. Liu HS, Jan MS, Chou CK, Chen PH, Ke NJ. Is green fluorescent protein toxic to living cells? Biochem Biophys Res Commun 1999; 260:712-717.
28. Troyano A, Fernandez C, Sancho P, de Blas E, Aller P. Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation. J Biol Chem 2001; 276:47107-47115.
29. Kovacic P, Osuna JA. Mechanisms of anti-cancer agents: emphasis on oxidative stress and electron transfer. Curr Pharm Des 2000; 6:277-309.
30. Steinbauer M, Guba M, Cernaianu G, Kohl G, Getto M, Kunz-Schughart LA, et al. GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice. Clin Exp Metastasis 2003; 20:135-141.
31. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshhinka H, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001; 61:241-249.
32. Ledley FD, Soriano HE, O'Malley BW, Lewis D, Darlington GJ, Finegold M. DiI as a marker for cellular transplantation into solid organs. Bio Techniques 1992; 13:581-587.
33. Honn KV, Busse WD, Sloane BF. Prostacyclin and thromboxanes. Implication for their role in tumor cell metastasis. Biochem Pharmacol 1983; 32:1-11.
34. Schneider MR, Tang DG, Schirner M, Honn KV. Prostacyclin and its analogues: antimetastatic effects and mechanism of action. Cancer Metastasis Rev 1994; 13:349-364.
35. Susuki K, Aiura K, Ueda M, Kitajima M. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelets agents. Pancreas 2004; 29:132-140.
36. Lee YC. The involvement of VEGF in endothelial permeability: a target for anti-inflammatory therapy. Curr Opin Investig Drugs 2005; 6:1124-1130.
37. Weiss SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005; 437:497-504.
38. Patel N, Sun L, Moshinsky D, Chen H, Leahy KM, Le P, et al. A selective and oral small molecule inhibitor of VEGFR-2 and VEGFR-1 inhibits neovascularuzation and vascular permeability. J Pharmacol Exp Ther 2003; 306:838-845.
39. Schirner M, Schneider MR. The prostacyclin analogue cicaprost inhibits metastasis of tumours of R 3327 MAT Lu prostate carcinoma and SMT 2A mammary carcinoma. J Cancer Res Clin Oncol 1992; 118:497-501.